2021 Disease Vaccine 
DrugBank
JULY 18, 2024
Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. This led to the eradication of smallpox and polio – two debilitating diseases that historically caused global epidemics. Sugars, such as sucrose are common stabilizers in many vaccines.
Eye on FDA
JANUARY 5, 2022
But before heading into 2022, it is perhaps time to take stock of AdComms and what they did or did not do during 2021. First and foremost is that as noted earlier this year (See August 5, 2021 FDA Adcomms – Is FDA Getting Less Advice? ), there were fewer 2021 meetings held to consider new drug applications than in years gone by.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 11, 2021
Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. based company has been in business for 10 years, but the COVID-19 vaccine was its first approved product. 18, 2020 ). It has already received $2.8
The Pharma Data
OCTOBER 14, 2021
Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose. Using data from the MS PATHS network in the U.S.,
The Pharma Data
SEPTEMBER 30, 2021
Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.
The Pharma Data
SEPTEMBER 30, 2021
As one among the leading global vaccines companies, we still bring options which help protect people’s health round the world,” said Michael Greenberg, MD, MPH, Medical Head, Sanofi Pasteur North America. “As 4,5 Anyone can get meningococcal disease, but teens and young adults are among those that are at the very best risk for the infection.6,7
The Pharma Data
JANUARY 4, 2021
.” Britain to Try Mix-and-Match COVID-19 Vaccinations. If a second dose of the first COVID-19 vaccine isn’t available or the maker isn’t known, then another vaccine may be used, new British guidelines say, The New York Times reported Sunday. Britain has green-lighted vaccines from Pfizer and AstraZeneca.
Expert insights. Personalized for you.
79 
Let's personalize your content